{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,8]],"date-time":"2026-01-08T01:49:18Z","timestamp":1767836958700,"version":"3.49.0"},"reference-count":47,"publisher":"Oxford University Press (OUP)","issue":"3","license":[{"start":{"date-parts":[[2005,1,26]],"date-time":"2005-01-26T00:00:00Z","timestamp":1106697600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2005,1,26]]},"abstract":"<jats:title>Summary<\/jats:title><jats:p>Inflammatory bowel diseases are chronic inflammatory disorders of the gastrointestinal tract. Vasoactive intestinal peptide (VIP) is a neuropeptide with known anti-inflammatory activity. We have demonstrated previously that administration of VIP inhibits leucocyte migration in a murine model of delayed-type hypersensitivity, and anti-inflammatory efficacy is supported by other studies. The aim of this study was to investigate the VIP effects in a murine model of intestinal inflammation. Colitis was induced in BALB\/c mice by a 2\u00b75\u2003mg enema of 2,4,6-trinitrobenzenesulphonic acid (TNBS) and the mice were killed on day 7. Mice were administered either a 3-day (therapeutic) or 7-day (prophylactic) constant infusion of VIP by subcutaneously implanted mini-osmotic pumps, or intraperitoneal (i.p.) injection of VIP on alternate days over 7\u2003days. Clinical disease scores, weight changes, histopathology of colon tissues, plasma VIP levels, cytokine levels and chemotaxis of peripheral blood mononuclear cells were evaluated. After administration of TNBS, mice quickly developed severe colitis accompanied by dramatic body weight loss (20% by day 6) and high mortality (30%). Prophylactic treatment using high-dose VIP abrogated leucocyte chemotaxis; however, it failed to ameliorate the weight loss and mortality. Moreover, VIP delivered either by constant infusion or i.p. failed to modify the clinical, histological or cytokine markers of disease. Our studies show that, despite an ability to inhibit chemokine-induced chemotaxis of mononuclear cells, VIP was unable to modulate TNBS-induced colitis. This contrasts with the efficacy of VIP in models of mild inflammatory disease and suggests that VIP is unlikely to provide a useful model for novel anti-IBD therapy.<\/jats:p>","DOI":"10.1111\/j.1365-2249.2005.02673.x","type":"journal-article","created":{"date-parts":[[2005,2,23]],"date-time":"2005-02-23T13:14:44Z","timestamp":1109164484000},"page":"411-420","source":"Crossref","is-referenced-by-count":36,"title":["Vasoactive intestinal peptide impairs leucocyte migration but fails to modify experimental murine colitis"],"prefix":"10.1093","volume":"139","author":[{"given":"R","family":"Newman","sequence":"first","affiliation":[{"name":"Department of Medicine, St George Clinical School, Kogarah, NSW, Australia"},{"name":"School of Medical Sciences, University of New South Wales, Sydney, NSW, Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"N","family":"Cuan","sequence":"additional","affiliation":[{"name":"Department of Medicine, St George Clinical School, Kogarah, NSW, Australia"},{"name":"School of Medical Sciences, University of New South Wales, Sydney, NSW, Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"T","family":"Hampartzoumian","sequence":"additional","affiliation":[{"name":"School of Medical Sciences, University of New South Wales, Sydney, NSW, Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S J","family":"Connor","sequence":"additional","affiliation":[{"name":"Department of Medicine, St George Clinical School, Kogarah, NSW, Australia"},{"name":"School of Medical Sciences, University of New South Wales, Sydney, NSW, Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A R","family":"Lloyd","sequence":"additional","affiliation":[{"name":"School of Medical Sciences, University of New South Wales, Sydney, NSW, Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M C","family":"Grimm","sequence":"additional","affiliation":[{"name":"Department of Medicine, St George Clinical School, Kogarah, NSW, Australia"},{"name":"School of Medical Sciences, University of New South Wales, Sydney, NSW, Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2005,1,26]]},"reference":[{"key":"2022010900430408000_b1","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1016\/S0952-7915(99)00032-1","article-title":"Animal models of mucosal inflammation and their relation to human inflammatory bowel disease","volume":"11","author":"Blumberg","year":"1999","journal-title":"Curr Opin Immunol"},{"key":"2022010900430408000_b2","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/S0140-6736(02)07284-7","article-title":"Crohn's disease","volume":"359","author":"Shanahan","year":"2002","journal-title":"Lancet"},{"key":"2022010900430408000_b3","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1146\/annurev.immunol.20.100301.064816","article-title":"The immunology of mucosal models of inflammation","volume":"20","author":"Strober","year":"2002","journal-title":"Annu Rev Immunol"},{"key":"2022010900430408000_b4","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1016\/S1471-4914(03)00052-2","article-title":"Mouse models for the study of Crohn's disease","volume":"9","author":"Pizarro","year":"2003","journal-title":"Trends Mol Med"},{"key":"2022010900430408000_b5","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1016\/0016-5085(89)90904-9","article-title":"Hapten-induced model of chronic inflammation and ulceration in the rat colon","volume":"96","author":"Morris","year":"1989","journal-title":"Gastroenterology"},{"key":"2022010900430408000_b6","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1016\/S0016-5085(99)70392-6","article-title":"Anti-interleukin 12 treatment regulates apoptosis of Th1 T cells in experimental colitis in mice","volume":"117","author":"Fuss","year":"1999","journal-title":"Gastroenterology"},{"key":"2022010900430408000_b7","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1084\/jem.182.5.1281","article-title":"Antibodies to interleukin 12 abrogate established experimental colitis in mice","volume":"182","author":"Neurath","year":"1995","journal-title":"J Exp Med"},{"key":"2022010900430408000_b8","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.4049\/jimmunol.157.3.1261","article-title":"Disparate CD4+ lamina propria (LP) lymphokine secretion profiles in inflammatory bowel disease. Crohn's disease LP cells manifest increased secretion of IFN-gamma, whereas ulcerative colitis LP cells manifest increased secretion of IL-5","volume":"157","author":"Fuss","year":"1996","journal-title":"J Immunol"},{"key":"2022010900430408000_b9","first-page":"823","article-title":"Type 1 T-helper cell predominance and interleukin-12 expression in the gut of patients with Crohn's disease","volume":"150","author":"Parronchi","year":"1997","journal-title":"Am J Pathol"},{"key":"2022010900430408000_b10","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1038\/nm0602-567","article-title":"The role of Th1\/Th2 polarization in mucosal immunity","volume":"8","author":"Neurath","year":"2002","journal-title":"Nat Med"},{"key":"2022010900430408000_b11","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1002\/jlb.67.3.267","article-title":"Insights from mouse models of colitis","volume":"67","author":"Boismenu","year":"2000","journal-title":"J Leukoc Biol"},{"key":"2022010900430408000_b12","first-page":"36","article-title":"Introduction and overview: recent advances in the immunotherapy of inflammatory bowel disease","volume":"38","author":"Hibi","year":"2003","journal-title":"J Gastroenterol"},{"key":"2022010900430408000_b13","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1007\/s003840000227","article-title":"Animal models of intestinal inflammation: new insights into the molecular pathogenesis and immunotherapy of inflammatory bowel disease","volume":"15","author":"Wirtz","year":"2000","journal-title":"Int J Colorectal Dis"},{"key":"2022010900430408000_b14","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1517\/14656566.1.4.615","article-title":"TNF-alpha antagonists for the treatment of Crohn's disease","volume":"1","author":"Kam","year":"2000","journal-title":"Expert Opin Pharmacother"},{"key":"2022010900430408000_b15","doi-asserted-by":"crossref","first-page":"89","DOI":"10.2174\/1381612013398374","article-title":"Immunology of VIP: a review and therapeutical perspectives","volume":"7","author":"Gomariz","year":"2001","journal-title":"Curr Pharm Des"},{"key":"2022010900430408000_b16","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1007\/s00109-001-0291-5","article-title":"Vasoactive intestinal peptide in the immune system: potential therapeutic role in inflammatory and autoimmune diseases","volume":"80","author":"Delgado","year":"2002","journal-title":"J Mol Med"},{"key":"2022010900430408000_b17","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1749-6632.1988.tb26968.x","article-title":"Vasoactive intestinal polypeptide and related peptides. Isolation and chemistry","volume":"527","author":"Mutt","year":"1988","journal-title":"Ann NY Acad Sci"},{"key":"2022010900430408000_b18","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1006\/frne.1995.1003","article-title":"Pituitary adenylate cyclase activating polypeptide (PACAP) and its receptors. neuroendocrine and endocrine interaction","volume":"16","author":"Arimura","year":"1995","journal-title":"Front Neuroendocrinol"},{"key":"2022010900430408000_b19","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/S1043-2760(05)80006-2","article-title":"Vasoactive intestinal polypepide \u2212 biological role in health and disease","volume":"2","author":"Said","year":"1991","journal-title":"Trends Endocrinol Metabolism"},{"key":"2022010900430408000_b20","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/S0167-5699(99)01525-X","article-title":"Immunobiology of vasoactive intestinal peptide (VIP)","volume":"21","author":"Pozo","year":"2000","journal-title":"Immunol Today"},{"key":"2022010900430408000_b21","doi-asserted-by":"crossref","first-page":"4213","DOI":"10.4049\/jimmunol.163.8.4213","article-title":"VIP and PACAP differentially regulate the costimulatory activity of resting and activated macrophages through the modulation of B7.1 and B7.2 expression","volume":"163","author":"Delgado","year":"1999","journal-title":"J Immunol"},{"key":"2022010900430408000_b22","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/S0165-5728(99)00105-8","article-title":"Shedding of membrane-bound CD14 from lipopolysaccharide-stimulated macrophages by vasoactive intestinal peptide and pituitary adenylate cyclase activating polypeptide","volume":"99","author":"Delgado","year":"1999","journal-title":"J Neuroimmunol"},{"key":"2022010900430408000_b23","doi-asserted-by":"crossref","first-page":"2907","DOI":"10.4049\/jimmunol.166.5.2907","article-title":"Is vasoactive intestinal peptide a type 2 cytokine?","volume":"166","author":"Delgado","year":"2001","journal-title":"J Immunol"},{"key":"2022010900430408000_b24","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.4049\/jimmunol.162.2.1200","article-title":"Vasoactive intestinal peptide (VIP) and pituitary adenylate cyclase-activation polypeptide (PACAP) protect mice from lethal endotoxemia through the inhibition of TNF-\u03b1 and IL-6","volume":"162","author":"Delgado","year":"1999","journal-title":"J Immunol"},{"key":"2022010900430408000_b25","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1002\/1529-0131(200201)46:1<271::AID-ART10039>3.0.CO;2-C","article-title":"Therapeutic effect of vasoactive intestinal peptide in collagen-induced arthritis","volume":"46","author":"Williams","year":"2002","journal-title":"Arthritis Rheum"},{"key":"2022010900430408000_b26","doi-asserted-by":"crossref","first-page":"4990","DOI":"10.4049\/jimmunol.171.10.4990","article-title":"Cutting edge: vasoactive intestinal peptide acts as a potent suppressor of inflammation in vivo by trans-deactivating chemokine receptors","volume":"171","author":"Grimm","year":"2003","journal-title":"J Immunol"},{"key":"2022010900430408000_b27","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1053\/gast.2003.50141","article-title":"Therapeutic effects of vasoactive intestinal peptide in the trinitrobenzene sulfonic acid mice model of Crohn's disease","volume":"124","author":"Abad","year":"2003","journal-title":"Gastroenterology"},{"key":"2022010900430408000_b28","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1084\/jem.188.2.317","article-title":"Opiates transdeactivate chemokine receptors: delta and mu opiate receptor-mediated heterologous desensitization","volume":"188","author":"Grimm","year":"1998","journal-title":"J Exp Med"},{"key":"2022010900430408000_b29","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1136\/gut.41.4.487","article-title":"Prophylactic effect of dietary glutamine supplementation on interleukin 8 and tumour necrosis factor alpha production in trinitrobenzene sulphonic acid induced colitis","volume":"41","author":"Ameho","year":"1997","journal-title":"Gut"},{"key":"2022010900430408000_b30","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1076\/apab.110.1.74.905","article-title":"Acute and chronic regulation of pituitary receptors for vasopressin and corticotropin releasing hormone","volume":"110","author":"Mason","year":"2002","journal-title":"Arch Physiol Biochem"},{"key":"2022010900430408000_b31","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1007\/s002689900401","article-title":"Cytokines in inflammatory bowel disease","volume":"22","author":"Rogler","year":"1998","journal-title":"World J Surg"},{"key":"2022010900430408000_b32","doi-asserted-by":"crossref","first-page":"2518","DOI":"10.1023\/A:1026606904531","article-title":"Effects of local budesonide treatment on the cell-mediated immune response in acute and relapsing colitis in rats","volume":"43","author":"Palmen","year":"1998","journal-title":"Dig Dis Sci"},{"key":"2022010900430408000_b33","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1111\/j.1440-1681.1992.tb00409.x","article-title":"Mechanism and prevention of chronic colonic inflammation with trinitrobenzene sulfonic acid in rats","volume":"19","author":"Hoshino","year":"1992","journal-title":"Clin Exp Pharmacol Physiol"},{"key":"2022010900430408000_b34","doi-asserted-by":"crossref","first-page":"C15","DOI":"10.1007\/BF01991017","article-title":"Chronic intrajejunal TNBS application in TNBS-sensitized rats: a new model of chronic inflammatory bowel diseases","volume":"Spec","author":"Selve","year":"1992","journal-title":"Agents Actions"},{"key":"2022010900430408000_b35","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1084\/jem.189.8.1169","article-title":"Hapten-induced colitis is associated with colonic patch hypertrophy and T helper cell 2-type responses","volume":"189","author":"Dohi","year":"1999","journal-title":"J Exp Med"},{"key":"2022010900430408000_b36","doi-asserted-by":"crossref","first-page":"1743","DOI":"10.1002\/eji.1830270722","article-title":"Predominant pathogenic role of tumor necrosis factor in experimental colitis in mice","volume":"27","author":"Neurath","year":"1997","journal-title":"Eur J Immunol"},{"key":"2022010900430408000_b37","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.4049\/jimmunol.161.3.1069","article-title":"Curative treatment of an experimentally induced colitis by a CD44 variant V7-specific antibody","volume":"161","author":"Wittig","year":"1998","journal-title":"J Immunol"},{"key":"2022010900430408000_b38","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1111\/j.1365-2249.1995.tb08363.x","article-title":"Anti-CD11b\/CD18 antibodies reduce inflammation in acute colitis in rats","volume":"101","author":"Palmen","year":"1995","journal-title":"Clin Exp Immunol"},{"key":"2022010900430408000_b39","doi-asserted-by":"crossref","first-page":"2766","DOI":"10.1172\/JCI119823","article-title":"Therapeutic effects of interleukin-4 gene transfer in experimental inflammatory bowel disease","volume":"100","author":"Hogaboam","year":"1997","journal-title":"J Clin Invest"},{"key":"2022010900430408000_b40","doi-asserted-by":"crossref","first-page":"1625","DOI":"10.1007\/BF02087911","article-title":"Protection by recombinant human interleukin-11 against experimental TNB-induced colitis in rats","volume":"41","author":"Qiu","year":"1996","journal-title":"Dig Dis Sci"},{"key":"2022010900430408000_b41","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/S0022-1759(02)00414-3","article-title":"Chemokine receptors in inflammation: an overview","volume":"273","author":"D\u2019Ambrosio","year":"2003","journal-title":"J Immunol Meth"},{"key":"2022010900430408000_b42","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1016\/S0016-5085(99)70345-8","article-title":"Protection of trinitrobenzene sulfonic acid-induced colitis by an interleukin 2-IgG2b fusion protein in mice","volume":"117","author":"Stallmach","year":"1999","journal-title":"Gastroenterology"},{"key":"2022010900430408000_b43","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1084\/jem.192.1.41","article-title":"Treatment of experimental (trinitrobenzene sulfonic acid) colitis by intranasal administration of transforming growth factor (TGF)-beta1 plasmid. TGF-beta1-mediated suppression of T helper cell type 1 response occurs by interleukin (IL)-10 induction and IL-12 receptor beta2 chain downregulation","volume":"192","author":"Kitani","year":"2000","journal-title":"J Exp Med"},{"key":"2022010900430408000_b44","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1172\/JCI200316750","article-title":"Anti-inflammatory properties of the micro opioid receptor support its use in the treatment of colon inflammation","volume":"111","author":"Philippe","year":"2003","journal-title":"J Clin Invest"},{"key":"2022010900430408000_b45","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1084\/jem.193.7.827","article-title":"Attenuation of colon inflammation through activators of the retinoid X receptor (RXR)\/peroxisome proliferator-activated receptor gamma (PPARgamma) heterodimer. A basis for new therapeutic strategies","volume":"193","author":"Desreumaux","year":"2001","journal-title":"J Exp Med"},{"key":"2022010900430408000_b46","doi-asserted-by":"crossref","first-page":"1912","DOI":"10.1053\/gast.2002.37050","article-title":"Curcumin prevents and ameliorates trinitrobenzene sulfonic acid-induced colitis in mice","volume":"123","author":"Sugimoto","year":"2002","journal-title":"Gastroenterology"},{"key":"2022010900430408000_b47","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/S0140-6736(73)91947-8","article-title":"Vasoactive intestinal polypeptide and watery-diarrhea syndrome","volume":"2","author":"Bloom","year":"1973","journal-title":"Lancet"}],"container-title":["Clinical and Experimental Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1365-2249.2005.02673.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/cei\/article-pdf\/139\/3\/411\/42082489\/j.1365-2249.2005.02673.x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/cei\/article-pdf\/139\/3\/411\/42082489\/j.1365-2249.2005.02673.x.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,2]],"date-time":"2023-05-02T08:12:26Z","timestamp":1683015146000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/cei\/article\/139\/3\/411\/6440570"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,1,26]]},"references-count":47,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2005,1,26]]},"published-print":{"date-parts":[[2005,1,26]]}},"URL":"https:\/\/doi.org\/10.1111\/j.1365-2249.2005.02673.x","relation":{},"ISSN":["1365-2249","0009-9104"],"issn-type":[{"value":"1365-2249","type":"electronic"},{"value":"0009-9104","type":"print"}],"subject":[],"published-other":{"date-parts":[[2005,3]]},"published":{"date-parts":[[2005,1,26]]}}}